骨髓瘤干细胞通过通过DRP1保持线粒体动态稳定性来抵抗化疗
Boren Tian1, Yaxuan Wu1, Xiaoyun Du2
1MOE Key Laboratory of Gene Function and Regulation, School of Life Sciences, Sun Yat‑sen University, Guangzhou, Guangdong 510275, P.R. China.
International journal of molecular medicine
|November 8, 2024
概括
骨髓瘤干细胞 (OSCs) 由于稳定的线粒体而抵抗化疗. 在OSC中准胺相关蛋白1 (DRP1) 可能会克服这种化学抵抗,改善骨髓瘤治疗.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 线粒体生物学 线粒体生物学
背景情况:
- 骨髓瘤与耐化疗骨髓瘤干细胞 (OSCs) 呈现异质性.
- 线粒体平衡的改变可能会影响OSCs中的化学抵抗.
- 线粒体稳定性在OSC化学抵抗中的确切作用尚不清楚.
研究的目的:
- 为了研究线粒体形态学,恒常状态和骨髓瘤干细胞中的化学抵抗之间的关系.
- 探索胺相关蛋白1 (DRP1) 在维护OSCs中的线粒体稳定性和化学抵抗性的作用.
主要方法:
- 高分辨率显微镜用于定量分析线粒体形态学.
- 用西斯 (CIS) 和多克索鲁比辛 (DOX) 治疗OSCs.
- 在OSC中基因操纵胺相关蛋白1 (DRP1) (耗尽和淘汰赛).
主要成果:
- 与非OSC相比,OSCs具有更大的线粒体.
- 与非OSC不同的是,OSC在CIS或DOX治疗时保持线粒体形态稳定性.
- DRP1的枯竭破坏了线粒体的稳定性,并减少了OSCs中用CIS或DOX治疗的化学抵抗.
结论:
- 由DRP1调节的线粒体平衡,对于骨髓瘤干细胞的化学抵抗至关重要.
- 准DRP1是一个潜在的治疗策略,可以提高骨髓瘤治疗的疗效.
- 这项研究揭示了骨髓瘤中化学抵抗的新型机制.
相关概念视频
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Mesenchymal Stem Cells
4.6K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.6K
Electron Transport Chain: Complex I and II
11.9K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
11.9K


